Plans to invest Rs 100 crores in the initial phase, to bring high-end clinical research and advanced medical engineering technologies
Apex Medical Corporation, headquartered in Taiwan, has made its debut into Indian market with the launch of its three main product verticals – Respiratory, Support Surface and Autoclaves primarily as their core offering in India. Reportedly, the company has a long term plan for the Indian market and will proceed in phases in a strategic manner. In coming few years, with an aggressive growth plan, Apex in India expects to grow at a CAGR of 30 per cent.
Speaking at the occasion, Daniel Lee, CEO, Apex Medical Corp, said, “We look forward to be part of this continuously growing healthcare industry in India. As the Indian market is growing at seven to eight per cent with healthcare market growing at 12-15 per cent, we expect Apex in India to grow at least by five times in the next five years.”
“Following our mission ‘Care for a Healthy Life’, we intend to offer best quality products at best and most affordable prices to medical personnel, care-givers and consumers in the sub-continent. We constantly strive to transform and better the lives of our customers through innovative products backed by cutting edge R&D and advanced technologies. The launch of our three main product verticals in India represents an exciting first step and we are confident that we will receive a positive response from this important market,” he further added.
Puneet Sahai, President, Apex Medical India, said, “We are excited to introduce FDA and CE approved Apex Products with technological excellence to customers in India at affordable prices well supported by high service standards. We aim to provide better environment for every patient striving for excellence in healthcare.”